SCM
MLYS icon

Sterling Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Sterling Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.45K Sell
202
-104
-34% -$2.85K ﹤0.01% 2562
2026
Q1 		$8.29K Hold
306
– – ﹤0.01% 2481
2025
Q4 		$11.1K Buy
306
+211
+222% +$8.46K ﹤0.01% 2552
2025
Q3 		$3.6K Hold
95
– – ﹤0.01% 2866
2025
Q2 		$1.28K Sell
95
-297
-76% -$4.3K ﹤0.01% 3018
2025
Q1 		$6.22K Sell
392
-331
-46% -$3.81K ﹤0.01% 2048
2024
Q4 		$8.9K Buy
723
+646
+839% +$8.45K ﹤0.01% 2212
2024
Q3 		$932 Buy
+77
New +$932 ﹤0.01% 2568

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Sterling Capital Management's MLYS Position: Q2 2026 in Review

Sterling Capital Management reduced its Mineralys Therapeutics (MLYS) stake by 34% in Q2 2026, selling an estimated $2.85K and leaving 202 shares worth $5.45K. The position accounts for ﹤0.01% of the portfolio, ranked #2562.

Sterling Capital Management first reported a position in MLYS in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.1K in Q4 2025. 61 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Sterling Capital Management held 202 shares of Mineralys Therapeutics worth $5.45K as of Q2 2026.
  • Sterling Capital Management sold 104 Mineralys Therapeutics shares in Q2 2026, an estimated $2.85K.
  • Mineralys Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2562 holding.
  • Sterling Capital Management first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Mineralys Therapeutics position peaked at $11.1K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.